Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00228007 · ClinicalTrials.gov registry record · Phase 3
Antidepressant Medication for Reducing HIV Risk Behavior in Depressed Intravenous Drug Users
A Phase 3 study, sponsored by Butler Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 265
- Enrollment target
NCT00228007: Completed Phase 3 study, sponsored by Butler Hospital.
NCT00228007 is a Phase 3 study that has completed, run by Butler Hospital. The registered enrollment target is 265 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00228007, a Phase 3 study, has completed, sponsored by Butler Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 265 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness of antidepressant medication treatment in reducing HIV risk behaviors in intravenous drug users with depression.
Interventions
- DRUG Antidepressant Medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2000-09 |
| Est. Completion | 2004-09 |
| Phase | Phase 3 |
What the finished NCT00228007 record still lists
NCT00228007 is an interventional study that assigns participants to a tested intervention. The registered 265 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 1 intervention - of which Antidepressant Medication is the first listed.
NCT00228007 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00228007 about?
NCT00228007 is a clinical study titled "Antidepressant Medication for Reducing HIV Risk Behavior in Depressed Intravenous Drug Users". This study will evaluate the effectiveness of antidepressant medication treatment in reducing HIV risk behaviors in intravenous drug users with depression.
What is the current status of trial NCT00228007?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 265 participants. The study started on 2000-09. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00228007?
The interventions under investigation include: Antidepressant Medication (DRUG).
Who is sponsoring clinical trial NCT00228007?
This trial is sponsored by Butler Hospital, which has 103 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00228007's enrollment target sits among peer trials
265 1223rd of 2000 higher than 776 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443126 · 265 participants · Phase 1
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
- NCT05470491 · 265 participants · Phase 1
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- NCT07301905 · 265 participants · NA
Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI
- NCT07470853 · 265 participants · Phase 1
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia